Systemic sclerosis & Raynaud's
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases
Authors' conclusion
There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety.
Study context
- Population
- Patients with connective tissue disease (CTD)-associated ILD treated with nintedanib (age 61.6 ± 13.2 years; 38 women, 13 men); SSc most common CTDretrospectively analysed · SSc most common CTD 32
- Participants
- 51 patients
- Exposure
- Nintedanib started at reduced dose vs standard dose of 300 mg
- Standard dosagen = 18reference
- Reduced dosagen = 33
- Outcome
- Cumulative discontinuation rate due to adverse events
Main finding
As reported in the abstract
- Comparable cumulative discontinuation rates due to adverse events in both groups
Observational data: associations, not effects.
Secondary outcomes
Maintenance dose
- No significant differences between the two groups
Cumulative dose · up to 52 weeks
- Lower in the reduced dosage group than in the standard dosage group
Changes in forced vital capacity (FVC)
- No significant differences between the two groups
Safety
Frequency of adverse events
- Similar frequencies in both groups
Original publication
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases. Scand J Rheumatol. Published 2 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →